scholarly journals Beneficial Effects of Addition of Glucocorticoid during Induction of Ovulation by Letrozole in Polycystic Ovarian Syndrome

2012 ◽  
Vol 4 (2) ◽  
pp. 85-89
Author(s):  
Mosammat Rashida Begum ◽  
Maruf Siddiqui ◽  
Hosne Ara Baby ◽  
Mariya Ehsan ◽  
Mosammat Shahina Begum ◽  
...  
Keyword(s):  
South Asian ◽  
Polycystic Ovarian Syndrome ◽  
Target Population ◽  
Research Centre ◽  
Induction Of Ovulation ◽  
Medical College ◽  
Beneficial Effects ◽  
Baseline Characteristics ◽  
Infertile Patients ◽  
Ovarian Syndrome

ABSTRACT Objective The aim of the study was to explore the efficacy of glucocorticoid in folliculogenesis and ovulation during induction of ovulation by letrozole in polycystic ovarian syndrome (PCOS). Materials and methods This experimental study was conducted in Dhaka Medical College and Hospital and Infertility Care and Research Centre (ICRC) Dhaka, Bangladesh. Two hundred and eighty infertile patients with PCOS, who failed to ovulate by letrozole 10 mg/day for 5 days were the target population of this study. The patients received glucocorticoid (Dexamethasone) 0.5 mg every alternate day from D2 of the cycle till D10 along with same dose of letrozole in subsequent cycles. Only letrozole-treated cycles were taken as control and letrozole plus glucocorticoid-treated cycles were taken as experimental. Monitoring was done by transvaginal ultrasonography. Six ovulatory cycles were observed for pregnancy. Main outcome measures were ovulation and pregnancy. Results Baseline characteristics were similar as same patients were taken as control and experimental. One hundred and eighty-two (65%) patients were ovulated and 93 (33.21%) patients got pregnant after addition of glucocorticoid. Conclusion In PCOS addition of glucocorticoid during induction of ovulation appears to cause significant improvement in folliculogenesis, ovulation and pregnancy. How to cite this article Begum MR, Ehsan M, Begum MS, Khan F, Baby HA, Siddiqui M, Quadir E. Beneficial Effects of Addition of Glucocorticoid during Induction of Ovulation by Letrozole in Polycystic Ovarian Syndrome. J South Asian Feder Obst Gynae 2012;4(2):85-89.

Characteristics of Polycystic Ovarian Syndrome in Sub-fertile Woman Attending to GOPD in ShSMCH

2019 ◽  
Vol 11 (1) ◽  
pp. 17-23
Author(s):  
Jinnat Ara Islam ◽  
Fatema Ashraf ◽  
Eva Rani Nandi
Keyword(s):  
Polycystic Ovarian Syndrome ◽  
Polycystic Ovaries ◽  
Cross Sectional ◽  
Medical College ◽  
Appropriate Treatment ◽  
Pcos Group ◽  
Symptom Complex ◽  
Ovarian Syndrome ◽  
Selection Of ◽  
Fertile Women

Background: Polycystic ovarian syndrome (PCOS) is a condition characterized by menstrual abnormalities (oligo/amenorrhea) and clinical or biochemical features of hyperandrogenism and may manifest at any age. It is a common cause of female subfertility. All the dimensions of PCOS have not been yet completely explored. Methods: It was a cross sectional comparative study carried out at-GOPD of Shaheed Suhrawardy Medical College & Hospital from January, 2016 to December 2016 on 162 subfertile women. Among them 54 were PCOS group and 108 were non PCOS group. PCOS was diagnosed by (Rotterdam criteria 2003) (i) Oligo or anovulation (ii) hyperandrogenism (iii) Polycystic ovaries. Study was done to evaluate and compare the demographic characteristics, clinical, biochemical and ultrasoundgraphic features of sub-fertile women with and without PCOS. Results: A total of 162 sub-fertile women aged 16-36 years. Mean age was 29.5±5.4. There were significant differences between the two groups in terms of (oligo/amenorrhea), hirsutism, WHR and ovarian ultrasound features. There were no significant differences between two groups in correlations between the level of obesity with the incidence of anovulation, hyperandrogenism or with hormonal features. Conclusion: PCOS is one of the important factors causing Infertility. It is an ill-defined symptom complex needed due attention. There is a need to increase awareness regarding. The clinical features of PCOS are heterogenous thus can be investigated accordingly of selection of appropriate treatment modality. J Shaheed Suhrawardy Med Coll, June 2019, Vol.11(1); 17-23

Effect of Sildenafil in Endometrial Ripening with Induction of Ovulation by Clomiphene Citrate in Polycystic Ovarian Syndrome; Double Blinded; Randomized Controlled Trial

2019 ◽  
Vol 2 (3) ◽  
pp. 01-10
Author(s):  
Dalia Mohammed Mohammed El-Khaldy ◽  
Mohamed Saeed Khallaf ◽  
Ahmed Mohamed Nour Eldin Hashad ◽  
Ibrahim Shazly Mohamed Amen Elshazly
Keyword(s):  
Randomized Controlled Trial ◽  
Polycystic Ovarian Syndrome ◽  
Controlled Trial ◽  
Clomiphene Citrate ◽  
Clinical Pregnancy ◽  
Sildenafil Citrate ◽  
Control Group ◽  
Induction Of Ovulation ◽  
Randomized Controlled ◽  
Ovarian Syndrome

Back ground: World Health Organization (WHO) defines infertility as a disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse. Worldwide, 8 to 12 percent of couples experience fertility problems. Causes of infertility in women were as follows: menstrual disorders (disorders of cycle length and flow) 62.6%, diseases (obesity, thyroid diseases, diabetes) 58.7%, impaired ovulation (hormonal disorders, oligoovulation and anovulation) 50.3%, uterine causes 16.7%, tubal factor 15.4%, and cervical causes 7.9%. In the male factor fertility there was semen abnormalities (44.6%), genetic factors (29.8%), anti-spermatogenesis agents (11%), and vascular disorders (17.2%). Aim of the Study: The purpose of this study is to evaluate the effect of sildenafil in endometrial ripening with induction of ovulation by clomiphene citrate in polycystic ovarian syndrome. Patients and methods: It is a randomized controlled trial on 65 infertile women with polycystic ovarian syndrome; patients were randomly divided into two equal groups. In control group, 31 patients were given oral sildenafil, one tablet every 12 hrs. From 2nd day of the cycle till 12th day and clomiphene citrate, one tablet every 12 hours, for 5 days from 3rd day of the menstrual cycle. In study group, 34 patients were given oral placebo, one tablet every 12 hrs. From 2nd day of the cycle till 12th day and clomiphene citrate, one tablet every 12 hours, for 5 days from 3rd day of the menstrual cycle. A transvaginal ultrasound was performed to evaluated the endometrial thickness before and after treatment, the follicularometeric was measured on day 11 and day13. Uterine artery Doppler was then measured. Qualitative serum B-hCG level was checked 14 days after ovulation to assess clinical pregnancy rate. Design: Prospective, Double blinded randomized controlled trial. Setting: Obstetrics & Gynecology outpatient clinic, Ain Shams University Hospital. Study duration: 3 months. Results: The present study was a double-blind, randomized, controlled study that was conducted on 65 women with PCOS who underwent induction of ovulation by Clomiphene citrate in outpatient clinic of Ain Shams University hospital. Conclusion: Our systematic review and meta-analysis showed that follicular supplementation of sildenafil citrate (oral or vaginal), alone or adjuvant therapy can be used for improving the EM and clinical pregnancy rate in women undergoing assisted reproduction. However, given the methodological limitations the current evidence does not support its use in clinical practice yet. Future high-quality RCT with large sample size to evaluate the sildenafil citrate effect in women undergoing assisted reproduction are needed. Future RCTs should focus on type of processing, stage of embryo, embryo quality, dosage, time of administration, type of control group, in order to identify the groups of patients who would benefit the most from this intervention and the most appropriate dosage, time, and type of sildenafil citrate which would have the most positive effect and the less possible side effects.

scholarly journals Effect of Myoinositol and Metformin in combination on clinical and hormonal profile in patients of polycystic ovarian syndrome

2019 ◽  
Vol 8 (2) ◽  
pp. 702
Author(s):  
Tripti Nagaria ◽  
Arpita Mohapatra ◽  
Jyoti Jaiswal
Keyword(s):  
Prospective Observational Study ◽  
Polycystic Ovarian Syndrome ◽  
Drug Dosage ◽  
Clinical Profile ◽  
Cutaneous Manifestations ◽  
Medical College ◽  
Maximum Improvement ◽  
Androgenic Hormone ◽  
Ovarian Syndrome ◽  
Spontaneous Onset

Background: Polycystic ovarian syndrome (PCOS) also known as hyperandrogenic anovulation syndrome or Stein – Leventhal syndrome is an endocrine disorder, characterized by anovulation, oligomenorrhea, amenorrhea, features of androgenic hormone excess (hirsutism, acne, alopecia, seborrhea) and insulin resistance. The global prevalence ranges from 2.2% to 26%. Methods: A prospective observational study was conducted from December 2015 to December 2016 in Department of Obstetrics and Gynecology at Pt. Jawahar Lal Nehru Memorial medical college and associated Dr. Bhim Rao Ambedkar memorial hospital, Raipur (C.G.) after obtaining permission of ethical committee of the institute to evaluate the effect of myoinositol and metformin on clinical profile in patients of polycystic ovarian syndrome. 70 women were included in the study who received a combination of myoinositol 600mg and metformin 500mg (twice a day) for 3 months for the management of PCOS. Prior to the start of the therapy, a detailed history and baseline investigations were recorded. Cases were reassessed at the end of three months of therapy for evaluation of change in clinical and hormonal profile.Results: 90.09% (63/70) cases showed improvement in the menstrual complaints. Spontaneous onset of menses occurred in all the cases presented with amenorrhea, in nearly 90% within 2 months of start of treatment. Regularization of cycles was observed in nearly 50% of patients with infrequent menses. Amongst all the cases with cutaneous manifestations, maximum improvement was seen in cases of acne (4/6) i.e. 66.66%. 25% (5/20) patients with infertility conceived during the study period.Conclusions: Myoinositol with metformin in combination has resulted in significant improvement in the clinical profile with reduction in individual drug dosage in cases with PCOS.

scholarly journals A randomized placebo controlled trial of metformin alone and metformin plus fixed dose combination of cyproterone acetate and ethinyl estradiol in hirsute women with polycystic ovarian syndrome

2018 ◽  
Vol 7 (5) ◽  
pp. 1011
Author(s):  
Shivani Jalota ◽  
Jatinder Singh ◽  
Ravi Saini
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Cyproterone Acetate ◽  
Polycystic Ovarian Syndrome ◽  
Ethinyl Estradiol ◽  
Chief Complaint ◽  
Fixed Dose ◽  
Beneficial Effects ◽  
Dose Combination ◽  
Ovarian Syndrome

Background: Polycystic ovarian syndrome is a common endocrine disorder seen in reproductive age group. Hirsutism, oligomennorhea and infertility being the most common chief complaint. Oral contraceptives have shown their efficacy in hirsute females. Metformin, an insulin sensitizer, have also shown some beneficial effects in improving metabolic abnormalities. Aim of this study is to compare the efficacy of metformin alone and metformin with fixed dose combination of cyproterone acetate and ethinyl estradiol in hirsute women with PCOS.Methods: 60 females of PCOS with chief complaint of hirsutism were enrolled. Patients were randomized to either metformin and Diane -35 (35 microgram ethinyl estradiol plus 2mg cyproterone acetate) or metformin and placebo for 9 months. Ferriman Gallwey score and body mass index was calculated at baseline, 3months, 6months and 9 months. FSH/LH/Prolactin/Testosterone/Fasting glucose and Fasting insulin levels were measured at the baseline and at the end of treatment.Results: Majority of females enrolled in the study were in third decade of life. Metformin and Diane- 35 showed higher reduction in Ferriman Gallwey score but Body mass index was reduced in both the groups. There was no significant difference seen between the groups with respect to biochemical profile.Conclusions: This data show that a combination of metformin and contraceptive pill may be more effective in treating hirsutism than metformin alone. Beneficial effects of therapy were seen in relation to BMI as well. Hence, combination therapy is better therapeutic option for treating hirsutism in PCOS. 

Sign in / Sign up

Export Citation Format

Share Document